Nuovo ospedale di Prato

Prato 59100

1 studies enrolling now · 4 studies all time

What they study most

Breast Cancer, Conventional Chondrosarcoma, Endometrial Cancer, HER-2 Positive Breast Cancer, Metastatic Neoplasm

Studies at this site

• Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer — Recruiting now
• Study of INBRX-109 in Conventional Chondrosarcoma — Running, not enrolling
• Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma — Running, not enrolling
• Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer — Completed